Cure­Vac’s In­g­mar Ho­err tells us why he re­turned to take on a pan­dem­ic; NGM los­es a pres­i­dent

On Tues­day, In­g­mar Ho­err stood up from his seat at the head of Cure­Vac’s board of di­rec­tors meet­ing in Frank­furt, Ger­many and walked out the door.

For 18 years, Ho­err had led the com­pa­ny he found­ed, stew­ard­ing it even when in­vestors re­buffed both him and his ap­proach, be­fore 2 years ago hand­ing it off to Daniel Menichel­la, a long­time biotech busi­ness ex­ec­u­tive who could fu­el the fi­nan­cial half of things. Now the world was fac­ing a pan­dem­ic and Cure­Vac might be able to build a vac­cine and the board, Ho­err said, want­ed some­one who knew the sci­ence back in charge.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.